dr. low on osimertinib versus dacomitinib in egfr-mutant nsclc
Published 4 years ago • 797 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:34
dr. fidler on the utility of dacomitinib in egfr-mutant nsclc
-
2:23
dr. zhu on primary resistance to osimertinib in egfr-mutant nsclc
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
1:21
dr. kris on the fda approval of dacomitinib in egfr nsclc
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
5:48
dr vamshi krishna | osimertinib vs dacomitinib
-
1:21
dr. bertino on frontline dacomitinib in metastatic egfr nsclc
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
1:57
dr. piotrowska on treatment for egfr-mutant nsclc
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
2:16
dr. rotow on results of a phase 1/2 trial with osimertinib/gefitinib in egfr-mutant nsclc
-
1:31
dr. gold on the future of osimertinib in lung cancer
-
1:53
resistance to osimertinib in egfr-mutated nsclc
-
1:01
dr. shum on emerging targeted therapies in egfr-mutant nsclc
-
2:20
osimertinib with chemotherapy in egfr-mutated nsclc | nejm
-
1:07
dr. garassino on immunotherapy in egfr-mutated lung cancer
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc